Corrigendum to “Silencing adenosine A2a receptor enhances dendritic cell-based cancer immunotherapy” [Nanomedicine Nanotechnol Biol Med 29 (2020) 102240]
Ali Masjedi(Tabriz University of Medical Sciences), Farhad Jadidi‐Niaragh(Tabriz University of Medical Sciences), Afshin Namdar(University of Alberta), Armin Ahmadi(University of Alabama in Huntsville), Mahzad Irandoust(Tabriz University of Medical Sciences), Sima Heydarzadeh Asl(Tabriz University of Medical Sciences), Mohsen Nabi‐Afjadi(Tarbiat Modares University), Mohammad Hojjat‐Farsangi(Karolinska University Hospital), Fariba Karoon Kiani(Tabriz University of Medical Sciences), Farinaz Malakotikhah(Islamic Azad University of Falavarjan), Hadi Hassannia(Mazandaran University of Medical Sciences), Ghasem Ghalamfarsa(Yasuj University of Medical Sciences), Sepideh Ghanee(Tabriz University of Medical Sciences), Fatemeh Atyabi(Tehran University of Medical Sciences)
Cited by 0
Related Papers
Nanoparticles and targeted drug delivery in cancer therapy
|Immunology Letters|2017|507
The significant role of interleukin-6 and its signaling pathway in the immunopathogenesis and treatment of breast cancer
|Biomedicine & Pharmacotherapy|2018|312
The paradox of Th17 cell functions in tumor immunity
|Cellular Immunology|2017|222
Small-Molecule Inhibitors of the Receptor Tyrosine Kinases: Promising Tools for Targeted Cancer Therapies
|International Journal of Molecular Sciences|2014|202
A role for Th1-like Th17 cells in the pathogenesis of inflammatory and autoimmune disorders
|Molecular Immunology|2018|194